Cargando…

Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies

Poly(ADP-ribose) polymerase-1 (PARP-1) and PARP-2 are enzymes which post-translationally modify proteins through poly(ADP-ribosyl)ation (PARylation)—the transfer of ADP-ribose chains onto amino acid residues—with a resultant modulation of protein function. Many targets of PARP-1/2-dependent PARylati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yélamos, José, Moreno-Lama, Lucia, Jimeno, Jaime, Ali, Syed O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072203/ https://www.ncbi.nlm.nih.gov/pubmed/32046278 http://dx.doi.org/10.3390/cancers12020392

Ejemplares similares

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
por: van Beek, Lotte, et al.
Publicado: (2021)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
por: Maluchenko, Natalya, et al.
Publicado: (2022)

PARP-1/PARP-2 double deficiency in mouse T cells results in faulty immune responses and T lymphomas
por: Navarro, Judith, et al.
Publicado: (2017)

PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites
por: Lin, Xiaohui, et al.
Publicado: (2022)

Differential regulation of breast cancer bone metastasis by PARP1 and PARP2
por: Zuo, Hao, et al.
Publicado: (2020)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

Are PARPs promiscuous?
por: Feijs, Karla L.H., et al.
Publicado: (2022)

Resistance to PARP-Inhibitors in Cancer Therapy
por: Montoni, Alicia, et al.
Publicado: (2013)

Different regulation of PARP1, PARP2, PARP3 and TRPM2 genes expression in acute myeloid leukemia cells
por: Gil-Kulik, Paulina, et al.
Publicado: (2020)

Uncoupling of PARP1 Trapping and Inhibition Using Selective PARP1 Degradation
por: Wang, Shuai, et al.
Publicado: (2019)

Dual function of HPF1 in the modulation of PARP1 and PARP2 activities
por: Kurgina, Tatyana A., et al.
Publicado: (2021)

Mono-ADP-ribosylation by PARP10 and PARP14 in genome stability
por: Dhoonmoon, Ashna, et al.
Publicado: (2023)

Clinical PARP inhibitors allosterically induce PARP2 retention on DNA
por: Langelier, Marie-France, et al.
Publicado: (2023)

The role of PARP inhibitor combination therapy in ovarian cancer
por: Hockings, Helen, et al.
Publicado: (2023)

ADP-ribosyltransferases Parp1 and Parp7 safeguard pluripotency of ES cells
por: Roper, Stephen J., et al.
Publicado: (2014)

Serine-linked PARP1 auto-modification controls PARP inhibitor response
por: Prokhorova, Evgeniia, et al.
Publicado: (2021)

PARP-2 and PARP-3 are selectively activated by 5′ phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1
por: Langelier, Marie-France, et al.
Publicado: (2014)

Overlapping roles for PARP1 and PARP2 in the recruitment of endogenous XRCC1 and PNKP into oxidized chromatin
por: Hanzlikova, Hana, et al.
Publicado: (2017)

HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer
por: Ma, Hanlin, et al.
Publicado: (2022)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

ADP-ribosyltransferase PARP11 suppresses Zika virus in synergy with PARP12
por: Li, Lili, et al.
Publicado: (2021)

PARP14 is a PARP with both ADP-ribosyl transferase and hydrolase activities
por: Đukić, Nina, et al.
Publicado: (2023)

Investigation of PARP-1, PARP-2, and PARG interactomes by affinity-purification mass spectrometry
por: Isabelle, Maxim, et al.
Publicado: (2010)

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma
por: Gill, Sonja J., et al.
Publicado: (2015)

A single nucleotide variant of human PARP1 determines response to PARP inhibitors
por: Cashman, Rivki, et al.
Publicado: (2020)

A two-step mechanism governing PARP1-DNA retention by PARP inhibitors
por: Xue, Huijun, et al.
Publicado: (2022)

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
por: Ding, Xia, et al.
Publicado: (2022)

The telomeric PARP, tankyrases, as targets for cancer therapy
por: Seimiya, H
Publicado: (2006)

Successes and Challenges of PARP Inhibitors in Cancer Therapy
por: Ricks, Tiffany K., et al.
Publicado: (2015)

Integration of PARP-inhibitors in ovarian cancer therapy
por: Pietragalla, Antonella, et al.
Publicado: (2020)

PARP inhibitors: its role in treatment of cancer
por: Chen, Alice
Publicado: (2011)

Role of Biomarkers in the Development of PARP Inhibitors
por: Ganguly, Bratati, et al.
Publicado: (2016)

The Nucleolus and PARP1 in Cancer Biology
por: Engbrecht, Marina, et al.
Publicado: (2020)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

The multifunctional protein YB-1 potentiates PARP1 activity and decreases the efficiency of PARP1 inhibitors
por: Alemasova, Elizaveta E., et al.
Publicado: (2018)

Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors
por: Marques, Maud, et al.
Publicado: (2015)

Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3
por: Sherstyuk, Yuliya V., et al.
Publicado: (2019)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qdtcie1b8g3bad7in2cop9tls9